



ten23 health's VIVA2 large-scale pre-filled syringe, cartridge, and vial aseptic Filling Line 2 in Switzerland GMP operational by end 2024

Basel, Switzerland, 18 of March 2024. ten23 health®, a leading Swiss contract development and manufacturing organization, today announced that its VIVA2 aseptic large-scale pre-filled syringe (PFS), vial and cartridge Filling Line 2 will be GMP operational by the end of 2024. Located in Visp, Switzerland, a hub for innovation and excellence in the pharmaceutical sector, VIVA2 will provide state-of-the-art facilities for aseptic manufacturing of commercial and clinical pharmaceutical sterile products.

First announced in June, 2022, the project has met its key milestones: the VIVA2 superstructure and building has been completed, ten23 teams moved into the new VIVA2 offices in December 2023, and both the QC microbiology labs and the new filling line are on track to be GMP operational by the end of 2024.

VIVA2 encompasses an 8-headed "ahead-of-the-art" and Annex 1 compliant Isolator-in-class C based filling line, adding over 30 million units' capacity of sterile prefilled-syringes, cartridges, or vials. The new line will be able to fill glass and polymer containers of syringes, cartridges and vials, including 0.5 mL, 1 mL, 2.25 mL syringe formats as well as cartridges from 1.5, to 3, 3.5 and 10 mL sizes. The latter includes cartridges compatible for use in on-body-injector devices (OBIs), e.g. West's "SmartDose"™ or other large-volume SC devices. It also provides specific features that will ensure highest fill precision, absence of headspace and tight process controls as well as Annex 1 GMP compliance, including PUPSIT (pre- and post-use filter integrity testing), 100% weight control, robot-assisted out-of-the-nest filling, both peristaltic and piston filling pumps, and various stopper setting techniques.

The ribbon-cutting ceremony for the new building is scheduled for 23rd of September 2024 in Visp, Valais, Switzerland, featuring speeches from ten23

executives, and the opportunity for networking with industry professionals. This milestone event marks a significant step for ten23 health®, as the company continues to increase capacity and adding further capabilities to meet the growing demands of pharmaceutical and biotech industry. A third filling line, specializing in bulk vial filling and lyophilization, is planned to be GMP operational by the end of 2025.

“We are thrilled to announce the Grand Opening of our VIVA2 facility and that our Line 2 will be GMP operational at the end 2024,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO) of ten23 health®. *“This investment underscores our commitment to providing Swiss quality services to our customers and advancing innovation in the pharmaceutical industry.”*

“We invite our customers and partners to join us and mark their calendars, as we celebrate this exciting milestone,” added Mahler. *“Together, we look forward to collaboratively shaping the future of healthcare and driving positive outcomes for patients worldwide.”*

About ten23 health®

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health® is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About BASE® and VIVA®

BASE® and VIVA® are our two facilities in Basel and Visp, Switzerland. It stands for our roots in Basel and life and nature in Valais. We have a strong connection to the local region, and we value our roots, life and nature and provide Swiss Quality. At ten23 health we embrace diversity with employees from different nationalities while still cherishing traditions. We are proud to be an employer in Switzerland where we can show our commitment to Patients, People and Planet.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m – €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 79 489 39 05

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021